{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:27:44Z","timestamp":1791329264097,"version":"4.3.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ejca.2016.03.009","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T22:53:26Z","timestamp":1463698406000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review"],"prefix":"10.1016","volume":"61","author":[{"given":"Marieke","family":"Arts-de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi J.","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J.E.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"de Hullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marleen","family":"Kets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2016.03.009_bib1","first-page":"609","article-title":"Ovarian cancer: an overview","volume":"80","author":"Roett","year":"2009","journal-title":"Am Fam Physician"},{"issue":"15","key":"10.1016\/j.ejca.2016.03.009_bib2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2016.03.009_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3181a106d4","article-title":"ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome","volume":"113","author":"American College of Obstetricians and Gynecologists","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2016.03.009_bib4","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Alterkruse SF, et\u00a0al. SEER Cancer Statistics Review, 1975\u20132011, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2011\/; based on November 2013 SEER data submission."},{"issue":"11","key":"10.1016\/j.ejca.2016.03.009_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2016.03.009_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ejca.2016.03.009_bib7","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ajog.2004.02.067","article-title":"Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause","volume":"191","author":"Piek","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2010.06.003","article-title":"SGO White Paper on ovarian cancer: etiology, screening and surveillance","volume":"119","author":"Schorge","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2016.03.009_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.ejca.2016.03.009_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation","volume":"160","author":"Nelson","year":"2014","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ejca.2016.03.009_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/jmg.2003.017996","article-title":"A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO","volume":"41","author":"Evans","year":"2004","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.ejca.2016.03.009_bib14","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancer","volume":"91","author":"Antoniou","year":"2004","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2016.03.009_bib15","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1200\/JCO.2002.05.121","article-title":"BRCAPRO validation, sensitivity of genetic testing of BRCA1\/BRCA2, and prevalence of other breast cancer susceptibility genes","volume":"20","author":"Berry","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2016.03.009_bib16","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2016.03.009_bib17","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","article-title":"Limited family structure and BRCA gene mutation status in single cases of breast cancer","volume":"297","author":"Weitzel","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2016.03.009_bib18","series-title":"Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE clinical guideline 164","article-title":"Familial breast cancer","author":"NICE","year":"2013"},{"key":"10.1016\/j.ejca.2016.03.009_bib19","series-title":"Vierde druk: Stichting Opsporing Erfelijke tumoren en Vereniging Klinische Genetica Nederland, Werkgroep Klinische Oncogenetica","article-title":"Erfelijke tumoren: Richtlijnen voor diagnostiek en preventie","year":"2010"},{"key":"10.1016\/j.ejca.2016.03.009_bib20","series-title":"Including fallopian tube cancer and primary peritoneal cancer. NCCN guidelines version 3.2014","article-title":"Ovarian Cancer","year":"2014"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2008.10.007","article-title":"Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study","volume":"112","author":"Metcalfe","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2016.03.009_bib22","series-title":"Society of gynecologic oncology","article-title":"SGO clinical practice statement: genetic testing for ovarian cancer","author":"Society of Gynecologic Oncology","year":"2014"},{"issue":"5","key":"10.1016\/j.ejca.2016.03.009_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/humu.10123","article-title":"A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families","volume":"20","author":"Phelan","year":"2002","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.ejca.2016.03.009_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nm1196-1179","article-title":"Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families","volume":"2","author":"Tonin","year":"1996","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2016.03.009_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2014.05.002","article-title":"Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania","volume":"207","author":"Janavicius","year":"2014","journal-title":"Cancer Genet"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","article-title":"Founder BRCA1\/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control","volume":"1","author":"Janavicius","year":"2010","journal-title":"EPMA J"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmg.2012.12.007","article-title":"Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation","volume":"56","author":"Janavicius","year":"2013","journal-title":"Eur J Med Genet"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13353-014-0254-5","article-title":"Mutational analysis of BRCA1\/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1\/2 alterations detected by next generation sequencing","volume":"56","author":"Ratajska","year":"2015","journal-title":"J Appl Genet"},{"issue":"17","key":"10.1016\/j.ejca.2016.03.009_bib30","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1093\/hmg\/ddu172","article-title":"The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population","volume":"23","author":"Song","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"2 Pt 1","key":"10.1016\/j.ejca.2016.03.009_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy","volume":"120","author":"Schrader","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"44","key":"10.1016\/j.ejca.2016.03.009_bib32","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2016.03.009_bib34","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/1078-0432.CCR-07-4806","article-title":"BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark","volume":"14","author":"Soegaard","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2016.03.009_bib35","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejca.2003.09.016","article-title":"One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden","volume":"40","author":"Malander","year":"2004","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"10.1016\/j.ejca.2016.03.009_bib38","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejca.2016.03.009_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004347-200210000-00011","article-title":"Histopathologic features of genetically determined ovarian cancer","volume":"21","author":"Shaw","year":"2002","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10689-012-9518-6","article-title":"Adequacy of family history taking in ovarian cancer patients: a population-based study","volume":"11","author":"van Altena","year":"2012","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IGC.0b013e3182392714","article-title":"Family history and women with ovarian cancer: is it asked and does it matter?: an observational study","volume":"22","author":"Lanceley","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2016.03.009_bib42","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ejca.2016.03.009_bib43","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s10897-013-9598-y","article-title":"Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic","volume":"22","author":"Petzel","year":"2013","journal-title":"J Genet Couns"},{"issue":"3","key":"10.1016\/j.ejca.2016.03.009_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0b013e318280f2b4","article-title":"Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?","volume":"23","author":"Powell","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2013.05.003","article-title":"Keeping it simple: genetics referrals for all invasive serous ovarian cancers","volume":"130","author":"Demsky","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2016.03.009_bib46","article-title":"BRCA1\/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study","author":"Hoberg-Vetti","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2008.06.016","article-title":"What women with ovarian cancer think and know about genetic testing","volume":"111","author":"Lacour","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2016.03.009_bib48","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/IGC.0b013e3182994365","article-title":"Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"23","author":"Novetsky","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2011.09.040","article-title":"There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","volume":"124","author":"Meiser","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2016.03.009_bib51","doi-asserted-by":"crossref","first-page":"e95285","DOI":"10.1371\/journal.pone.0095285","article-title":"The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejca.2016.03.009_bib52","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2012.24","article-title":"Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer","volume":"307","author":"Hyman","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2016.03.009_bib54","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.03.009_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7353","key":"10.1016\/j.ejca.2016.03.009_bib56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejca.2016.03.009_bib57","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1634\/theoncologist.2012-0028","article-title":"BRCAness: finding the Achilles heel in ovarian cancer","volume":"17","author":"Rigakos","year":"2012","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejca.2016.03.009_bib58","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cancergen.2011.09.004","article-title":"Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer","volume":"204","author":"Weberpals","year":"2011","journal-title":"Cancer Genet"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib59","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.03.009_bib60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.2.514","article-title":"Impact of BRCA1\/BRCA2 mutation testing on psychologic distress in a clinic-based sample","volume":"20","author":"Schwartz","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2016.03.009_bib61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.breast.2012.02.004","article-title":"What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?","volume":"21","author":"Bosch","year":"2012","journal-title":"Breast"},{"issue":"32","key":"10.1016\/j.ejca.2016.03.009_bib62","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2010.33.1561","article-title":"Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?","volume":"29","author":"Halbert","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916001854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916001854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T01:07:22Z","timestamp":1567904842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916001854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":62,"alternative-id":["S0959804916001854"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.03.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}